<DOC>
	<DOCNO>NCT01767467</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity GSK Biologicals ' vaccine GSK1437173A subject age 18 year old blood cancer . The study evaluate safety-related event antibody cellular immune response study vaccine , compare placebo .</brief_summary>
	<brief_title>Study Assess Safety Immunogenicity GlaxoSmithKline ( GSK ) Biologicals ' Herpes Zoster Subunit ( HZ/su ) Vaccine Adults Aged 18 Years Older With Blood Cancers</brief_title>
	<detailed_description>Amendment protocol posting : Increase sample size , update country/region-specific information ( Sections 5 , 6 9 ) . Promotion secondary primary objective ; relate update primary secondary outcome measure ( Sections 4 7 ) .</detailed_description>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . Written inform consent obtain subject . A male female , age 18 year old time study entry . Subject diagnose one haematologic malignancy prior first vaccination receiving , schedule receive finish immunosuppressive cancer therapy treat condition . Life expectancy great equal 12 month , assess investigator . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol inthe study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Subject diagnose chronic lymphocytic leukaemia ( CLL ) receive oral cancer therapy ( subject receive intravenous cancer therapy CLL intravenous cancer therapy combination oral therapy may enrol ) . Subject receive radiotherapy alone treatment his/her haematologic malignancy . Planned haematopoietic stem cell transplant ( HCT ) study period . ( If HCT occur prior enrolment study , subject may receive study vaccine least 50 day transplant procedure ) . Human immunodeficiency virus ( HIV ) infection clinical history . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine/placebo , plan use study period . However , investigational use register product treat subject 's underlying disease , allow . Previous vaccination HZ varicella within 12 month precede first dose study vaccine/placebo . Planned administration study HZ varicella vaccine ( include investigational nonregistered vaccine ) study vaccine . Occurrence varicella HZ episode clinical history within 12 month precede first dose study vaccine/placebo . History reaction hypersensitivity likely exacerbate component vaccine . Administration plan administration live vaccine period start 30 day first dose study vaccine end 30 day last dose study vaccine . Administration plan administration nonreplicating vaccine within 8 day prior within 14 day either dose study vaccine . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution Month 3 ( i.e. , 2 month last dose study vaccine/placebo ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>Safety</keyword>
	<keyword>Herpes zoster</keyword>
	<keyword>Vaccination</keyword>
	<keyword>Haematologic malignancy</keyword>
</DOC>